For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Doximity (DOCS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Doximity is a member of the Medical sector. This group includes 1022 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks S ...

Market Overview - The U.S. equity markets have experienced significant volatility recently, with a postelection rally losing momentum due to concerns over potential policy changes under the new administration [1] - Apprehensions regarding the pace of interest rate cuts have also weighed on the markets, despite healthy economic growth providing some leeway for slower monetary easing [1] - Solid earnings from blue-chip technology stocks have contributed to a partial recovery in the markets [1] Momentum Investing Strategy - Investors are looking towards momentum stocks, such as Doximity, Inc. (DOCS), Impinj, Inc. (PI), and Innodata Inc. (INOD), as a strategy to generate sustained profits amid market uncertainty [2] - Momentum investing is based on the principle of "buying high and selling higher," capitalizing on established trends that are likely to continue due to existing momentum [3] - This strategy has been shown to generate alpha over long periods and across various market conditions, although it requires skill to detect trends effectively [4] Screening Parameters for Momentum Stocks - The screening process identifies the top 50 stocks with the best percentage price change over the last 52 weeks to ensure steady appreciation [5] - From these, the bottom 10 performers over the past week are selected to identify those experiencing short-term pullbacks [6] - Stocks with a Zacks Rank 1 (Strong Buy) and a Momentum Style Score of A or B are prioritized, as they have a proven history of outperformance [7] Selected Stocks - Doximity has seen a price increase of 113.8% over the past year but has declined by 14.8% in the past week, with a Momentum Score of A [9] - Impinj's stock has rallied 112.9% in the past year but has decreased by 11.7% in the past week, holding a Momentum Score of B [10] - Innodata has experienced a remarkable 380.2% increase in the past year, with a recent decline of 9.7% in the past week, and it has a Momentum Score of A [11]

Core Viewpoint - Doximity (DOCS) is positioned as a strong investment opportunity due to significant upward revisions in earnings estimates, indicating a positive earnings outlook and potential for continued stock price appreciation [1][2]. Current-Quarter Estimate Revisions - The earnings estimate for the current quarter is $0.31 per share, reflecting a year-over-year increase of +6.9% - Over the past 30 days, the Zacks Consensus Estimate for Doximity has risen by 11.56%, with four estimates moving higher and no negative revisions [4]. Current-Year Estimate Revisions - For the full year, Doximity is projected to earn $1.10 per share, representing a year-over-year change of +15.79% - The consensus estimate has increased by 5.65% over the past month, with five estimates moving higher and no negative revisions [5]. Favorable Zacks Rank - Doximity currently holds a Zacks Rank 1 (Strong Buy), indicating strong agreement among analysts regarding positive earnings revisions - Stocks with Zacks Rank 1 and 2 have historically outperformed the S&P 500 [6]. Stock Performance - Doximity shares have increased by 21.4% over the past four weeks, suggesting investor confidence in the company's earnings growth prospects [7].

Company Overview - Doximity positions itself as a digital platform for doctors, offering an integrated suite of tools for marketing, staffing, and workflow management, which includes telehealth, scheduling, and document management [1] Key Personnel - Michael (Mike) Dion is highlighted as an expert in FP&A, Corporate Finance, and Small Business, with 12 years of experience in Fortune 100 companies and a background in various industries such as Telecom, Media and Entertainment, Hospitality, and Construction [1] Investment Approach - The investment strategy focuses on identifying value opportunities where investors may overreact to negative news or underreact to positive news, emphasizing strong fundamentals and a preference for dividend-paying stocks [1]

Core Insights - Doximity shares surged nearly 40% in premarket trading following strong second quarter results and an optimistic outlook for the fiscal year [2][5] - The company reported $136.8 million in revenue for Q2 2025, a 20% increase year-over-year, surpassing analyst expectations of $128.4 million [3] - Doximity's profit for the quarter was $44.2 million, exceeding the projected $37.9 million [3] Revenue and User Metrics - Over 600,000 medical professionals utilized Doximity's networking and productivity tools in the quarter, indicating strong engagement [3] - The company projected third quarter revenue between $152 million to $153 million, above the analyst consensus of $142.7 million [4] - Doximity raised its full-year revenue guidance to a range of $535 million to $540 million, up from the previous range of $514 million to $523 million [5] Market Reaction - Following the earnings report, Doximity shares rose 38.6% to $60.19, marking the highest opening price since March 2022 [5]

INVESTOR PRESENTATION Fall 2024 LEGAL DISCLAIMER This presentation and associated commentary may contain forward-looking statements, including statements regarding expectations of future results of operations or financial performance of Doximity, market size and growth opportunities, the calculation of certain of our key financial and operating metrics, capital expenditures, plans for future operations, competitive position, technological capabilities, and strategic relationships, general business condition ...

Financial Data and Key Metrics Changes - Doximity reported revenue of $137 million for Q2 2025, representing a 20% year-on-year growth and a 7% beat from the high end of guidance [8] - Adjusted EBITDA margin reached a record 56%, amounting to $76 million, which is a 41% year-on-year growth and 20% above the high end of guidance [10][22] - The company generated free cash flow of $66.8 million in Q2, a 475% increase year-on-year, primarily driven by higher profits [23] Business Line Data and Key Metrics Changes - The top 20 clients grew by 24% on a trailing 12-month basis, indicating strong demand from major pharmaceutical companies [9] - Workflow tools contributed to 20% of pharma sales in Q2, with significant growth in telehealth and AI assistance tools [13][22] - The number of unique active prescribers reached over 600,000, showcasing the effectiveness of workflow tools [12] Market Data and Key Metrics Changes - The net revenue retention rate improved to 116% on a trailing 12-month basis, up from 114% in Q2 of the previous year [20] - The top 20 customers had a net revenue retention rate of 124%, up from 119% in Q2 of the previous year [21] Company Strategy and Development Direction - Doximity plans to roll out its client portal to all pharma clients starting early next year, prioritizing agency partnerships over SMB self-service [18] - The company is focusing on enhancing its workflow tools and AI capabilities, which are expected to drive future growth [29][77] - Doximity aims to leverage agency partnerships to expand its reach and improve efficiency in client engagement [70] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's competitive position, citing strong user growth and engagement metrics [34][108] - The outlook for Q3 2025 includes expected revenue in the range of $152 million to $153 million, representing 13% growth at the midpoint [26] - Management noted that while the market is stabilizing, the growth rate for pharma budgets is expected to remain in the mid-single digits for the near term [90] Other Important Information - Doximity's client portal has shown strong engagement, with clients spending more time on the platform than expected [54] - The company repurchased $22.1 million worth of shares during Q2, reducing fully diluted shares outstanding by approximately 4% since Q2 of the previous year [25] Q&A Session Summary Question: What factors contributed to the revenue upside? - Management indicated that the upside was due to market stabilization, new product revenues, and share gains [34] Question: Why is Q4 revenue guidance conservative? - Management explained that clients are becoming more disciplined with their annual budgets, impacting revenue flow into Q4 [35][36] Question: What is the status of the self-serve portal? - The self-serve portal is expected to roll out to all clients early next year, with a focus on agency partnerships for growth [40][42] Question: How has engagement changed? - Engagement metrics have improved significantly, with record highs in article reads and workflow tool usage [47][49] Question: Are there differences in engagement by specialty? - Endocrinologists have been highlighted as heavy users of telehealth, contributing to overall engagement growth [57] Question: What are the investment priorities for the second half of the year? - Investment areas include hiring for commercial R&D and enhancing the client portal, with expected increases in commission payouts [63][64] Question: How is the competitive environment shaping up? - Management feels confident about gaining market share due to strong client relationships and product quality [108]

Core Viewpoint - Doximity reported quarterly earnings of $0.30 per share, exceeding the Zacks Consensus Estimate of $0.26 per share, and showing an increase from $0.22 per share a year ago, indicating a 15.38% earnings surprise [1] Financial Performance - Doximity's revenues for the quarter ended September 2024 were $136.83 million, surpassing the Zacks Consensus Estimate by 7.70% and up from $113.61 million year-over-year [2] - The company has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Stock Performance - Doximity shares have increased approximately 51% since the beginning of the year, compared to a 24.3% gain in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.28 on revenues of $140.06 million, and for the current fiscal year, it is $1.05 on revenues of $520.23 million [7] - The outlook for the Medical Services industry, where Doximity operates, is currently in the bottom 45% of Zacks industries, which may impact stock performance [8]

Revenue Growth - Revenue for the three months ended September 30, 2024 was $136.8 million, representing a year-over-year growth rate of 20%[129] - Revenue for the six months ended September 30, 2024 was $263.5 million, representing a year-over-year growth rate of 19%[129] - Revenue for the three months ended September 30, 2024 increased by $23.2 million (20%) compared to the same period in 2023, driven by a $23.0 million increase in subscription revenue[162] - Revenue for the six months ended September 30, 2024 increased by $41.4 million (19%) compared to the same period in 2023, primarily due to a $41.7 million increase in subscription revenue[162] Net Income and Margins - Net income for the three months ended September 30, 2024 was $44.2 million, compared to $30.6 million in the same period last year[129] - Net income margin for the three months ended September 30, 2024 was 32%, compared to 27% in the same period last year[139] - Net income for the three months ended September 30, 2024 increased by $13.6 million (44%) compared to the same period in 2023, with net income margin improving to 32% from 27%[161] - Net income for the six months ended September 30, 2024 increased by $26.5 million (45%) compared to the same period in 2023, with net income margin improving to 32% from 27%[161] Adjusted EBITDA - Adjusted EBITDA for the three months ended September 30, 2024 was $76.1 million, compared to $54.2 million in the same period last year[129] - Adjusted EBITDA margin for the three months ended September 30, 2024 was 56%, compared to 48% in the same period last year[139] Customer Metrics - Net revenue retention rate for the TTM ended September 30, 2024 was 116%, compared to 114% in the same period last year[134] - Number of customers with at least $500,000 of revenue for the TTM ended September 30, 2024 was 103, compared to 92 in the same period last year[133] - Customers with at least $500,000 of revenue accounted for approximately 83% of total revenue for the TTM ended September 30, 2024[132] Free Cash Flow - Free cash flow for the six months ended September 30, 2024 was $106.3 million, compared to $67.3 million in the same period last year[143] Gross Profit - Gross profit for the three months ended September 30, 2024 increased by $22.3 million (22%) compared to the same period in 2023, with gross margin improving to 90% from 89%[163] - Gross profit for the six months ended September 30, 2024 increased by $40.1 million (20%) compared to the same period in 2023, with gross margin improving to 90% from 88%[163] Research and Development Expenses - Research and development expense for the three months ended September 30, 2024 increased by $3.3 million (16%) compared to the same period in 2023, primarily due to a $2.9 million increase in stock-based compensation[166] - Research and development expense for the six months ended September 30, 2024 increased by $3.9 million (9%) compared to the same period in 2023, driven by a $4.3 million increase in stock-based compensation[167] Sales and Marketing Expenses - Sales and marketing expense for the three months ended September 30, 2024 increased by $4.2 million (14%) compared to the same period in 2023, primarily due to higher personnel-related expenses and advertising costs[153] - Sales and marketing expense for the three months ended September 30, 2024 increased by $4.2 million (14%) compared to the same period in 2023, driven by a $4.1 million increase in stock-based compensation and a $0.7 million increase in sales incentive compensation[168] - Sales and marketing expense for the six months ended September 30, 2024 increased by $5.0 million (8%) compared to the same period in 2023, driven by a $4.7 million net increase in stock-based compensation and a $1.7 million increase in sales incentive compensation[169] General and Administrative Expenses - General and administrative expense for the three months ended September 30, 2024 increased by $1.1 million (13%) compared to the same period in 2023, driven by higher compliance costs associated with being a publicly-traded company[154] - General and administrative expense for the three months ended September 30, 2024 increased by $1.1 million (13%) compared to the same period in 2023, primarily due to a $0.7 million increase in stock-based compensation and a $0.4 million increase in legal costs[170] - General and administrative expense for the six months ended September 30, 2024 increased by $1.1 million (6%) compared to the same period in 2023, primarily due to a $1.3 million increase in stock-based compensation and a $0.4 million increase in legal costs[171] Restructuring and Impairment - Restructuring and impairment charge for the three and six months ended September 30, 2024 was $2.3 million, a decrease of $5.6 million (71%) compared to the same periods in 2023, due to a sublease of office space in Irving, Texas[172] Other Income and Taxes - Other income, net for the three and six months ended September 30, 2024 increased by $3.1 million (53%) and $5.4 million (50%) respectively, driven by higher interest income from cash equivalents and marketable securities[174] - Provision for income taxes for the three and six months ended September 30, 2024 increased by $8.9 million (98%) and $14.6 million (96%) respectively, driven by higher income before taxes and decreased tax deductions from stock award activities[175] Cash and Marketable Securities - As of September 30, 2024, the company had $805.6 million in cash and cash equivalents and marketable securities, consisting of U.S. government and agency securities, corporate notes, and commercial paper[176] - As of September 30, 2024, the company had $184.2 million in cash and cash equivalents and $621.3 million in marketable securities, primarily in money market funds, corporate notes, and U.S. government securities[194] - A hypothetical 100 basis point increase in interest rates would decrease the market value of cash equivalents and marketable securities by $5.0 million and $3.4 million as of September 30, 2024 and March 31, 2024, respectively[196] Stock Repurchase Program - The company repurchased and retired 1,021,233 shares of Class A common stock under a $500 million repurchase program, with $470.0 million remaining authorized for repurchase as of September 30, 2024[178] Cash Flow Activities - Net cash provided by operating activities for the six months ended September 30, 2024 was $109.6 million, driven by net income of $85.5 million and non-cash items of $42.9 million, including $35.0 million in stock-based compensation[186] - Cash provided by investing activities was $67.2 million for the six months ended September 30, 2023, primarily from proceeds of $212.8 million from maturities of marketable securities and $37.5 million from sales of marketable securities, offset by $180.2 million in purchases and $2.7 million in software development costs[188] - Cash used in financing activities was $76.2 million for the six months ended September 30, 2024, mainly due to $74.2 million in common stock repurchases, $5.5 million in contingent consideration payments, and $8.2 million in taxes, partially offset by $10.2 million from stock option exercises and $1.4 million from employee stock purchase plan[188] - Cash used in financing activities was $186.9 million for the six months ended September 30, 2023, primarily from $186.2 million in common stock repurchases, $5.4 million in contingent consideration payments, and $4.1 million in taxes, partially offset by $7.2 million from stock option exercises and $1.5 million from employee stock purchase plan[189] Inflation Impact - The company does not believe inflation has had a material effect on its business, but significant inflationary pressures could harm its financial condition and results of operations if costs cannot be fully offset[197]

Exhibit 99.1 Doximity Announces Fiscal 2025 Second Quarter Financial Results Total revenues of $136.8 million, up 20% year-over-year Net income growth of 44% and adjusted EBITDA growth of 41% year-over-year SAN FRANCISCO, Calif., November 7, 2024 -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 second quarter ended September 30, 2024. "Our clinical workflow tools saw record use in Q2 with over 600,000 unique active prescr ...